The AI in life science market is projected to grow from about $21.6 billion in 2026 to roughly $69.3 billion by 2031, driven by data-oriented and agentic AI that enables self-acting systems for clinical trial optimization, real-world evidence collection, and post-market monitoring.

Cloud-based AI services are accelerating data consolidation from medical, genomic, and patient sources to support predictive modeling, with AI agents automating literature search, hypothesis formulation, and patient segmentation to boost efficiency.

Growth is driven by the convergence of advanced analytics, real-world data platforms, and intelligent automation across the pharma and healthcare value chain, alongside a shift toward AI-driven commercialization and autonomous execution.

Market offerings span end-to-end solutions, niche/point tools, and AI tech, with applications in drug discovery, clinical trials, quality assurance, and regulatory workflows, supported by tools like machine learning, NLP, and computer vision.

North America led the market in 2025, underpinned by early AI adoption, robust data infrastructure, interoperable data exchange, and a strong ecosystem of AI-native life sciences firms.

Pharma companies accounted for the largest share in 2025, with end-to-end solutions also comprising a substantial portion of the market, and North America holding the largest regional share.

North America’s leadership stemmed from early AI adoption, strong data infrastructure, interoperable data exchange, and a thriving ecosystem of AI-native startups and vendors serving discovery through post-market activities.

NLP developments include Anthropic's Claude for Healthcare and Microsoft Dragon Copilot, both advancing healthcare documentation automation in the early to mid-2020s.

Other tool segments encompass machine learning, context-aware processing, computing, computer vision, and image analysis, with cloud-based solutions dominating deployment due to scalability.

Leading players profiled include NVIDIA, Illumina, Tempus AI, Recursion Pharmaceuticals, Dassault Systèmes, Schrödinger, Microsoft, Insilico Medicine, Eurofins Discovery, BenevolentAI, Owkin, PathAI, Aidoc, Qure.ai, Deep Genomics, SOPHiA GENETICS, and Unlearn.AI.

The market size trajectory spans 2025 to 2031, with 2026 at about $21.6 billion and 2031 around $69.3 billion.

Notable industry developments include Oracle’s Life Sciences AI Data Platform launched in January 2026 and IQVIA’s AI agents introduced mid-2025 to optimize clinical and commercial workflows.